TEVA-LISINOPRIL/HCTZ (TYPE P) TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

LISINOPRIL (LISINOPRIL DIHYDRATE); HYDROCHLOROTHIAZIDE

から入手可能:

TEVA CANADA LIMITED

ATCコード:

C09BA03

INN（国際名）:

LISINOPRIL AND DIURETICS

投薬量:

10MG; 12.5MG

医薬品形態:

TABLET

構図:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG; HYDROCHLOROTHIAZIDE 12.5MG

投与経路:

ORAL

パッケージ内のユニット:

30/100

処方タイプ:

Prescription

治療領域:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0222417003; AHFS:

認証ステータス:

APPROVED

承認日:

2010-12-08

製品の特徴

PRODUCT MONOGRAPH
PR
TEVA-LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin Converting Enzyme Inhibitor/Diuretic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Control No: 169889
Date of Preparation:
November 26, 2010
Date of Revision:
January 21, 2014
TEVA-LISINOPRIL/HCTZ (TYPE P) Tablets
2
PRODUCT MONOGRAPH
Pr
TEVA-LISINOPRIL/HCTZ (TYPE P)
(lisinopril as lisinopril dihydrate and hydrochlorothiazide)
10/12.5 mg, 20/12.5 mg and 20/25 mg Tablets
Angiotensin-Converting Enzyme Inhibitor/Diuretic
ACTION AND CLINICAL PHARMACOLOGY
TEVA-LISINOPRIL/HCTZ (TYPE P) (lisinopril and hydrochlorothiazide
tablets) combines the
action of an angiotensin-converting enzyme (ACE) inhibitor,
lisinopril, and a diuretic,
hydrochlorothiazide.
LISINOPRIL
Angiotensin-converting enzyme (ACE) is a peptidyl dipeptidase which
catalyzes the conversion
of angiotensin I to the pressor substance, angiotensin II. Inhibition
of ACE results in decreased
plasma angiotensin II, which leads to increased plasma renin activity
(due to removal of negative
feedback of renin release) and decreased aldosterone secretion.
Although the latter decrease is
small, it results in a small increase in serum potassium. In patients
treated with lisinopril plus a
thiazide diuretic, there was essentially no change in serum potassium
(see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system,
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
PHARMACODYNAMICS
LISINOPRIL
Administration of lisinopril to patients with hypertension results in
a reduction of both supine
and standing blood pressure. Abrupt withdrawal of li